Reliable Clinical Chemistry and Biomarker Services

cvmd-magnifyglass.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Make Decisions with Confidence Early in Preclinical CVMD Research with CrownBio’s Reliable Clinical Chemistry and Biomarker Services

CrownBio offers clinical chemistry and biomarker services to provide robust, high quality data for the early preclinical development of CVMD drugs and diagnostics. Our expertise covers a range of models and therapeutic areas, with a particular focus on cardio-metabolic endpoints in rodents and non-human primates. CrownBio provides a rapid, cost effective way to analyze samples as a standalone service, or as a supplement to in vivo studies.

Non-GLP Clinical Chemistry and Biomarker Services

Analytes listed in the following sections are subject to change. Please contact your local business development specialist for our current offerings. Additional assays are available with a validation lead time of approximately 2-3 weeks.

Clinical Chemistry Services

CrownBio can efficiently analyze the effects of agents through a comprehensive portfolio of clinical chemistry assays that provide valuable information about drug efficacy, candidate selection, and enzymatic activity. The following portfolio of assays were developed on the Beckman-Coulter AU480 Chemical System and are available through CrownBio as a service to help advance preclinical cardiovascular and metabolic disease development programs:

View Clinical Chemistry Assays 


Biomarker Services

Translational biomarkers are used throughout drug development to help elucidate underlying pathophysiology, understand agents’ mechanisms of action, measure efficacy, and stratify patient populations. CrownBio recognizes the importance of biomarkers from target validation studies to candidate selection and our scientists can develop, validate, and run custom assay services in addition to the following set of immunoassay services routinely performed to help inform decision making in cardiovascular and metabolic disease development. Choose from the following platforms:

MesoScale Discovery Biomarker Assays

Run your samples on MSD’s electrochemiluminescent technology platform. Using the Sector S600, biomarkers can be customized into a V-PLEX or U-PLEX plate with up to 10 biomarkers of your choice.

View MesoScale Discovery Assays 


Colorimetric ELISA Biomarker Assays

Evaluate biomarkers on our standard, colorimetric, enzyme based ELISA platform.

View ELISA Assays 


Service Details

Turn Around Time: 5 to 7 business days (clinical chemistry), 7-10 business days (MSD & ELISA)
Data Delivery Format: Excel File, unless otherwise requested

Assay Validation

CrownBio recognizes the importance of providing reliable data to our clients, so we have instated rigorous quality control and assay qualification procedures to ensure precision and accuracy. We provide high quality results that our clients can trust when making go/no-go decisions in their CVMD preclinical research programs. Please see below for examples of standard curves generated for two important cytokines.

CrownBio’s custom-fit, 7-point standard curves used to calculate accurate and precise concentrations for IL-10 and TNF-α in client samples..